Get the latest news, insights, and market updates on HTGC (Hercules Capital, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Hercules Capital Issues New Notes While Shares Screen As Undervalued
Hercules Capital (NYSE:HTGC) has announced the issuance of new fixed-rate unsubordinated unsecured notes. The offering introduces additional fixed-income securities into the company’s capital structure. The notes are unsecured and unsubordinated, meaning they rank alongside other senior unsecured obligations of the company. Hercules Capital focuses on providing financing to growth-oriented companies, often in sectors where access to flexible capital is important. When a lender such as... Feb 5, 2026 - $HTGC
Hercules Capital (HTGC): Buy, Sell, or Hold Post Q3 Earnings?
Over the past six months, Hercules Capital’s stock price fell to $17.50. Shareholders have lost 9.6% of their capital, which is disappointing considering the S&P 500 has climbed by 10.2%. This might have investors contemplating their next move. Feb 4, 2026 - $HTGC
Affirm, Nubank, Enova, Hercules Capital, and Interactive Brokers Shares Are Soaring and Falling, What You Need To Know
A number of stocks traded in opposite directions in the afternoon session after the market slid following the release of weaker-than-expected private-sector employment data, fueling concerns about a cooling economy. According to the ADP report, U.S. private employers added only 22,000 jobs in January, falling significantly short of economists' estimates of 45,000. This miss signals that the multi-year cooling in labor demand has continued into the new year. The disappointing data added to existi Feb 4, 2026 - $HTGC
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update. The Company's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in anti-PD-1 failed melanoma wa Feb 3, 2026 - $HTGC
Is Hercules Capital (HTGC) Pricing Reflect Its Role In Funding High Growth Companies
If you are wondering whether Hercules Capital's current share price lines up with its underlying worth, you are not alone. This article is built to help you assess that value clearly. The stock recently closed at US$18.53, with a 1 year return of a 2.4% decline, a 3 year return of 75.0%, and a 5 year return of 104.1% that may catch your eye if you are weighing potential risk and reward. Recent coverage has highlighted Hercules Capital's role in funding high growth companies and its position... Feb 2, 2026 - $HTGC
The Exit Rush Is Over for Nontraded BDCs. Cash Keeps Coming Into Private Credit.
The once-hot business of private credit got ice buckets of bad news in recent months, with the publicized failures of some borrowers. Just last week, BlackRock disclosed a 19% write-down in the net asset value of the loans owned at BlackRock TCP Capital one of the business-development companies that private-credit firms market to individual investors. Most of the good-size BDCs have diverse portfolios and credit loss histories that are as good or better than other debt categories. Jan 31, 2026 - $HTGC
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple